Stocks
Merck & Co Financial Statements (MRK) |
||||||||||
| Merck & Cosmart-lab.ru | % | 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 07.08.2023 | 03.11.2023 | 31.12.2023 | 11.04.2024 | 03.05.2024 | 03.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 15 035 | 15 962 | 14 630 | 14 630 | 15 809 | 61 031 | |||
| Operating Income, bln rub | -4 861 | 5 998 | -299.0 | -299.0 | 5 917 | 11 317 | ||||
| EBITDA, bln rub | ? | -4 861 | 5 998 | 679.0 | 679.0 | 6 901 | 14 257 | |||
| Net profit, bln rub | ? | -5 975 | 4 745 | -1 226 | -1 226 | 4 762 | 7 055 | |||
| OCF, bln rub | ? | 3 704 | 7 717 | 246.0 | 246.0 | 3 090 | 11 299 | |||
| CAPEX, bln rub | ? | 965.0 | 902.0 | 989.0 | 989.0 | 861.0 | 3 741 | |||
| FCF, bln rub | ? | 2 739 | 6 815 | -743.0 | -743.0 | 2 229 | 7 558 | |||
| Dividend payout, bln rub | 1 885 | 1 855 | 1 852 | 1 852 | 1 950 | 7 509 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 39.1% | 0.00% | 0.00% | 40.9% | 106.4% | ||||
| OPEX, bln rub | 16 023 | 5 826 | 11 589 | 11 589 | 5 957 | 34 961 | ||||
| Cost of production, bln rub | 4 024 | 4 264 | 3 340 | 3 340 | 3 935 | 14 879 | ||||
| R&D, bln rub | 13 321 | 3 307 | 8 838 | 8 838 | 3 479 | 24 462 | ||||
| Interest expenses, bln rub | 277.0 | 317.0 | 310.0 | 310.0 | 303.0 | 1 240 | ||||
| Assets, bln rub | 104 469 | 106 727 | 106 675 | 106 675 | 105 849 | 105 849 | ||||
| Net Assets, bln rub | ? | 38 693 | 41 246 | 37 581 | 37 581 | 40 364 | 40 364 | |||
| Debt, bln rub | 36 911 | 34 859 | 36 268 | 36 268 | 34 219 | 34 219 | ||||
| Cash, bln rub | 6 422 | 8 812 | 7 161 | 7 161 | 5 711 | 5 711 | ||||
| Net debt, bln rub | 30 489 | 26 047 | 29 107 | 29 107 | 28 508 | 28 508 | ||||
| Ordinary share price, rub | 115.4 | 103.0 | 109.0 | 109.0 | 132.0 | 102.9 | ||||
| Number of ordinary shares, mln | 2 539 | 2 537 | 2 533 | 2 533 | 2 533 | 2 533 | ||||
| Market cap, bln rub | 292 975 | 261 184 | 276 148 | 276 148 | 334 229 | 260 570 | ||||
| EV, bln rub | ? | 323 464 | 287 231 | 305 255 | 305 255 | 362 737 | 289 078 | |||
| Book value, bln rub | -2 167 | 864 | -1 627 | -1 627 | 1 611 | 1 611 | ||||
| EPS, rub | ? | -2.35 | 1.87 | -0.48 | -0.48 | 1.88 | 2.79 | |||
| FCF/share, rub | 1.08 | 2.69 | -0.29 | -0.29 | 0.88 | 2.98 | ||||
| BV/share, rub | -0.85 | 0.34 | -0.64 | -0.64 | 0.64 | 0.64 | ||||
| EBITDA margin, % | ? | -32.3% | 37.6% | 4.64% | 4.64% | 43.7% | 23.4% | |||
| Net margin, % | ? | -39.7% | 29.7% | -8.38% | -8.38% | 30.1% | 11.6% | |||
| FCF yield, % | ? | 3.70% | 5.04% | 3.31% | 4.00% | 3.30% | 2.90% | |||
| ROE, % | ? | 8.04% | 11.2% | 0.97% | 6.14% | 5.71% | 17.5% | |||
| ROA, % | ? | 2.98% | 4.32% | 0.34% | 2.16% | 2.18% | 6.67% | |||
| P/E | ? | 94.2 | 56.7 | 756.6 | 119.8 | 144.9 | 36.9 | |||
| P/FCF | 27.1 | 19.8 | 30.2 | 25.0 | 30.3 | 34.5 | ||||
| P/S | ? | 5.02 | 4.40 | 4.59 | 4.49 | 5.44 | 4.27 | |||
| P/BV | ? | -135.2 | 302.3 | -169.7 | -169.7 | 207.5 | 161.7 | |||
| EV/EBITDA | ? | 47.9 | 33.6 | 53.7 | 35.0 | 41.6 | 20.3 | |||
| Debt/EBITDA | 4.52 | 3.05 | 5.12 | 3.34 | 3.27 | 2.00 | ||||
| R&D/CAPEX, % | 1 380% | 366.6% | 893.6% | 893.6% | 404.1% | 653.9% | ||||
| CAPEX/Revenue, % | 6.42% | 5.65% | 6.76% | 6.76% | 5.45% | 6.13% | ||||
| Merck & Co shareholders | ||||||||||
